Neos Therapeutics is a pharmaceutical company specializing in the development and production of products for the treatment of central nervous system (CNS) disorders. The company has a portfolio of products including Adzenys XR-ODT, Cotempla XR-ODT, and Adzenys-ER, all of which treat ADHD. In addition, the company is developing NT0502, a treatment for sialorrhea in patients with neurological conditions. Neos Therapeutics is a commercial-stage company listed on the NASDAQ under the ticker symbol NEOS.